Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

January 25, 2018 updated by: Maastricht Radiation Oncology

Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

Study Overview

Status

Completed

Conditions

Detailed Description

Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated.

Study Type

Observational

Enrollment (Actual)

155

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Maastricht, Netherlands, 6229 ET
        • Maastro clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with 1 upto 4 brain metastases treated with SRT

Description

Inclusion Criteria:

  • Cerebral metastasized patients

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics
Time Frame: 1 year
Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.
1 year
Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics
Time Frame: 1 year
Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
Time Frame: 1 year
Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
1 year
Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
Time Frame: 1 year
Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
1 year
Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
Time Frame: 1 year
Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area under the curve of published prognostic scores
Time Frame: 1 year
Area under the curve published prognostic scores
1 year
Mismatch rate of published prognostic scores
Time Frame: 1 year
Mismatch rate of published prognostic scores
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Maastricht Radiation Oncology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2014

Primary Completion (Actual)

September 4, 2014

Study Completion (Actual)

September 4, 2014

Study Registration Dates

First Submitted

October 1, 2014

First Submitted That Met QC Criteria

October 10, 2014

First Posted (Estimate)

October 16, 2014

Study Record Updates

Last Update Posted (Actual)

January 26, 2018

Last Update Submitted That Met QC Criteria

January 25, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Radiomics SRT 09-2014

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastases, Neoplasm

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe